inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Items 401–500 of 1,000
Biosynthesis of fatty acids and related metabolites
Rawlings, B. J. (1997) · Natural Product Reports · doi:10.1039/np9971400335 · Cited by 60
Evolution of Mycobacterium tuberculosis drug resistance in the genomic era
Nimmo, C., Millard, J., Faulkner, V., Monteserin, J., Pugh, H., & Johnson, E. O. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.954074 · Cited by 73
“inhA (isoniazid, ethionamide) Both drugs unable to bind NADH-dependent enoyl-acyl carrier protein reductase responsible for mycolic acid synthesis (Banerjee et al., 1994)”
BackgroundGemma, S., Savini, L., Altarelli, M., Tripaldi, P., Chiasserini, L., Coccone, S. S., Kumar, V., Camodeca, C., Campiani, G., Novellino, E., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.06.051 · Cited by 59
Gerusz, V. J., Denis, A., Faivre, F., Bonvin, Y., Oxoby, M., Briet, S., LeFralliec, G., Oliveira, C., Desroy, N., Raymond, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301113w · Cited by 59
Soutter, H. H., Clark, M., Cuozzo, J. W., Dumelin, C. E., Guié, M.-A., Habeshian, S., Keefe, A. D., Kennedy, K. M., Sigel, E. A., Troast, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610978113 · Cited by 59
“Plates were inoculated with Mtb and incubated for 5 d; growth was measured by OD590 and fluorescence (excitation 560/emission 590) using a BioTek Synergy 4 plate reader.”
BackgroundInfluentialCurrent and Potential Treatment of Tuberculosis
Houston, S. C., & Fanning, A. (1994) · Drugs · doi:10.2165/00003495-199448050-00004 · Cited by 68
Zabinski, R. F., & Blanchard, J. S. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9639731 · Cited by 59
Chang, A. T., Schiebel, J., Yu, W., Bommineni, G. R., Pan, P., Baxter, M. V., Khanna, A., Sotriffer, C., Kisker, C., & Tonge, P. J. (2013) · Biochemistry · doi:10.1021/bi400413c · Cited by 63
Pan, P., Knudson, S. E., Bommineni, G. R., Li, H., Lai, C., Liu, N., García–Díaz, M., Simmerling, C. L., Patil, S. S., Slayden, R. A., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300429 · Cited by 60
Luò, T., Zhao, M., Li, X., Xu, P., Gui, X., Pickerill, S., DeRiemer, K., Mei, J., & Gao, Q. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00964-09 · Cited by 58
“and the intergenic region of oxyR-ahpC (3, 33, 34, 37, 43).”
BackgroundBoyne, M. E., Sullivan, T. J., amEnde, C. W., Lu, H., Gruppo, V., Heaslip, D. G., Amin, A. G., Chatterjee, D., Lenaerts, A. J. M., Tonge, P. J., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00383-07 · Cited by 58
“While the exquisite potency of INH may result from a complex mode of action that still remains to be delineated completely (15), it is known that INH affects cell wall biosynthesis via alterations of the mycobacterial type II fatty acid biosynthesis (FAS-II) pathway, one mechanism of which is through inhibition of Inh…”
BackgroundHigh-Dose Isoniazid Therapy for Isoniazid-Resistant Murine Mycobacterium tuberculosis Infection
Cynamon, M. H., Zhang, Y., Harpster, T. S., Cheng, S. J., & DeStefano, M. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2922 · Cited by 60
Kamsri, P., Hanwarinroj, C., Phusi, N., Pornprom, T., Chayajarus, K., Punkvang, A., Suttipanta, N., Srimanote, P., Suttisintong, K., Songsiriritthigul, C., et al. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00918 · Cited by 59
Synthesis and evaluation of a novel series of pseudo-cinnamic derivatives as antituberculosis agents
Yoya, G. K., Bedos‐Belval, F., Constant, P., Duran, H., Daffé, M., & Baltas, M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.082 · Cited by 58
Pretorius, G. S., van Helden, P. D., Sirgel, F. A., Eisenach, K. D., & Victor, T. C. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.10.2276 · Cited by 64
“tuberculosis. One such alternative mechanismofresistancetoINHmayinvolvetheinhAgene,recently reported to be involved in resistance ( 2 ).”
BackgroundMolecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis
Rouse, D. A., & Morris, S. L. (1995) · Infection and Immunity · doi:10.1128/iai.63.4.1427-1433.1995 · Cited by 59
First– and Second–Line Drugs and Drug Resistance
Nath, H., & Ryoo, S. (2013) · InTech eBooks · doi:10.5772/54960 · Cited by 70
“Which is activated by EtaA/EthA (a mono-oxygenase) [90, 91] and inhibits the same target as INH, the InhA of the mycolic acid synthesis pathway [92].”
BackgroundTranscriptional regulation of lipid homeostasis in mycobacteria
Salzman, V., Mondino, S., Sala, C., Cole, S. T., Gago, G., & Gramajo, H. C. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07313.x · Cited by 63
“, 2005) and from their genetic and biochemical characterization as the target of several antimycobacterial drugs (Kilburn and Takayama, 1981; Quemard et al., 1991; Banerjee et al., 1994; Baulard et al., 2000), nothing is known about the transcriptional regulation of the FAS-II encoding genes.”
BackgroundLohrasbi, V., Talebi, M., Bialvaei, A. Z., Fattorini, L., Drancourt, M., Heidary, M., & Darban‐Sarokhalil, D. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.12.002 · Cited by 63
Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
Jhun, B. W., & Koh, W. (2019) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2019.0065 · Cited by 59
Haydel, S. E. (2010) · Pharmaceuticals · doi:10.3390/ph3072268 · Cited by 60
“Ethionamide resistance is linked to inhA mutations, whereby cross-resistance occurs between isoniazid and ethionamide [66,90], and to mutations in the etaA (ethA) gene, which codes for flavin monooxygenase responsible for activation of ethionamide [91,92].”
BackgroundInhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface
Abrahams, K. A., Cox, J. A. G., Fütterer, K., Rullás, J., Ortega-Muro, F., Loman, N. J., Moynihan, P. J., Pérez‐Herrán, E., Jiménez, E., Esquivias, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09642-y · Cited by 59
van Doorn, H. R., Kuijper, E. J., ENDE, A. V. D., Welten, A. G. A., van Soolingen, D., de Haas, P. E. W., & Dankert, J. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.4.1591-1594.2001 · Cited by 56
“In the last decade, mutations in katG (24, 26) and inhA (2) have been found to account for 60 to 70% and 10 to 15% of INH resistance cases among M.”
BackgroundSuperessential reactions in metabolic networks
Barve, A., Rodrigues, J. F. M., & Wagner, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113065109 · Cited by 68
da Silva, P. E. A., Ramos, D. F., Bonacorso, H. G., de la Iglesia, A. I., Oliveira, M. R., Coelho, T. S., Navarini, J., Morbidoni, H. R., Zanatta, N., & Martins, M. A. P. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.03.019 · Cited by 55
Metabolism of the Antituberculosis Drug Ethionamide
Vale, N., Gomes, P. A. C., & Santos, H. A. (2012) · Current Drug Metabolism · doi:10.2174/138920013804545151 · Cited by 58
“Gene array studies have shown that both ETH and INH induce similar patterns of protein expression [74], and mutations in the InhA gene give rise to resistance to both ETH and INH [45, 75].”
A Novel Mechanism of Growth Phase-dependent Tolerance to Isoniazid in Mycobacteria
Niki, M., Niki, M., Tateishi, Y., Ozeki, Y., Kirikae, T., Lewin, A., Inoue, Y., Matsumoto, M., Dahl, J. L., Ogura, H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.333385 · Cited by 70
“In its active form, INH inhibits both InhA, which is a primary target of INH (8), and an enoyl-acyl carrier protein reductase of the fatty acid synthase II (9, 10).”
BackgroundDrug-susceptibility testing in TB: current status and future prospects
Richter, E., Rüsch–Gerdes, S., & Hillemann, D. (2009) · Expert Review of Respiratory Medicine · doi:10.1586/ers.09.45 · Cited by 68
Angula, K. T., Legoabe, L. J., & Beteck, R. M. (2021) · Pharmaceuticals · doi:10.3390/ph14050461 · Cited by 59
Dual Inhibition of Mycobacterial Fatty Acid Biosynthesis and Degradation by 2-Alkynoic Acids
Morbidoni, H. R., Vilchèze, C., Kremer, L., Bittman, R., Sacchettini, J. C., & Jacobs, W. R. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.01.005 · Cited by 59
Self-citationOxidative Stress Increases Susceptibility of Mycobacterium tuberculosis to Isoniazid
Bulatović, V. M., Wengenack, N. L., Uhl, J. R., Hall, L., Roberts, G. D., Cockerill, F. R., & Rusnak, F. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2765-2771.2002 · Cited by 56
“INH-resistant M. tuberculosis has been associated with deletions or point mutations in the katG gene ( 1 , 12, 21, 24, 37, 45, 51, 53), with the threonine-for-serine substitution at position 315 (S315T) in katG being one of the most common mutations found in clinical isolates.”
BackgroundTB: the return of the phage. A review of fifty years of mycobacteriophage research.
McNerney, R. (1999) · PubMed · Cited by 55
Ando, H., Kitao, T., Miyoshi‐Akiyama, T., Kato, S., Mori, T., & Kirikae, T. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2011.07547.x · Cited by 55
“Activated INH inhibits the synthesis of essential mycolic acids by inactivating the NADH-dependent enoyl-acyl carrier protein reductase encoded by inhA (Banerjee et al., 1994; Vilcheze et al., 2006).”
BackgroundSCHROEDER, E., Basso, L. A., Santos, D. S., & de Souza, O. N. (2005) · Biophysical Journal · doi:10.1529/biophysj.104.053512 · Cited by 54
“Using a genetic approach, Jacobs and co-workers identified the protein product of the mycobacterial inhA gene as the putative target for INH inhibition (10).”
MethodTracking the Putative Biosynthetic Precursors of Oxygenated Mycolates of Mycobacterium tuberculosis
Dinadayala, P., Laval, F., Raynaud, C., Lemassu, A., Lanéelle, M., Lanéelle, G., & Daffé, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210501200 · Cited by 60
Genetics and pulmonary medicine bullet 5: Genetics of drug resistant tuberculosis
Telenti, A. (1998) · Thorax · doi:10.1136/thx.53.9.793 · Cited by 62
Rapid Detection of Pyrazinamide-Resistant Mycobacterium tuberculosis by a PCR-Based In Vitro System
Suzuki, Y., Suzuki, A., Tamaru, A., Katsukawa, C., & Oda, H. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.2.501-507.2002 · Cited by 66
Deretic, V. P., Pagán-Ramos, E., Zhang, Y., Dhandayuthapani, S., & Via, L. E. (1996) · Nature Biotechnology · doi:10.1038/nbt1196-1557 · Cited by 54
LipG a bifunctional phospholipase/thioesterase involved in mycobacterial envelope remodeling
Santucci, P., Point, V., Poncin, I., Guy, A., Crauste, C., Serveau, C., Galano, J., Spilling, C. D., Cavalier, J., & Canaan, S. (2018) · Bioscience Reports · doi:10.1042/bsr20181953 · Cited by 57
Chollet, A., Mourey, L., Lherbet, C., Delbot, A., Julien, S., Baltas, M., Bernadou, J., Pratviel, G., Maveyraud, L., & Bernardes‐Génisson, V. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.04.008 · Cited by 53
“On the one hand, it is the main target of the confirmed drugs INH and ethionamide (ETH) (Banerjee et al., 1994) and on the other hand, InhA, as all enzymes of the FAS-II system, does not have a human ortholog.”
BackgroundDrobniewski, F. A., Rüsch–Gerdes, S., & Hoffner, S. E. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01813.x · Cited by 64
The molecular basis of isoniazid resistance in Mycobacterium tuberculosis
Heym, B., Saint‐Joanis, B., & Cole, S. T. (1999) · Tubercle and Lung Disease · doi:10.1054/tuld.1998.0208 · Cited by 54
Pruksakorn, P., Arai, M., Liu, L., Moodley, P., Jacobs, W. R., & Kobayashi, M. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1287 · Cited by 55
Self-citationAlahari, A., Alibaud, L., Trivelli, X., Gupta, R., Lamichhane, G., Reynolds, R. C., Bishai, W. R., Guérardel, Y., & Kremer, L. (2009) · Molecular Microbiology · doi:10.1111/j.1365-2958.2009.06604.x · Cited by 62
“Several of the successful antimycobacterial drugs, including isoniazid (INH) or ethionamide (ETH), inhibit enzymes required for mycolic acid synthesis (Banerjee et al., 1994; Vilcheze et al., 2006; Wang et al., 2007).”
BackgroundAbe, C., Kobayashi, I., Mitarai, S., Wada, M., Kawabe, Y., Takashima, T., Suzuki, K., Sng, L., Wang, S., Htay, H., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00561-08 · Cited by 63
“tuberculosis resistance to INH and ETH may involve an altered level of InhA, an expression which may have been influenced by the sequence change in the regulatory region of the inhA locus (7, 25, 27).”
BackgroundManagement of children exposed to multidrug-resistant Mycobacterium tuberculosis
Seddon, J. A., Godfrey‐Faussett, P., Hesseling, A. C., Gie, R. P., Beyers, N., & Schaaf, H. S. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70366-8 · Cited by 52
Resistance in tuberculosis: what do we know and where can we go?
Green, K. D., & Garneau‐Tsodikova, S. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00208 · Cited by 62
“Mutations in InhA causing overexpression of the target (Baulard et al., 2000; Debarber et al., 2000; Larsen et al., 2002) or preventing binding of the active form of INH and ETH to the target (Banerjee et al., 1994; Vilcheze et al., 2008) also confer cross-resistance to these drugs.”
Cell Envelope Lipids in the Pathophysiology of Mycobacterium Tuberculosis
Singh, P., Rameshwaram, N. R., Ghosh, S., & Mukhopadhyay, S. (2018) · Future Microbiology · doi:10.2217/fmb-2017-0135 · Cited by 63
GENETICS OF DRUG RESISTANCE IN TUBERCULOSIS
Telenti, A. (1997) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70355-5 · Cited by 60
Matviiuk, T., Mori, G., Lherbet, C., Rodriguez, F., Pasca, M. R., Gorichko, M. V., Guidetti, B., Voïtenko, Z., & Baltas, M. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.069 · Cited by 51
Punkvang, A., Saparpakorn, P., Hannongbua, S., Wolschann, P., Beyer, A., & Pungpo, P. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.09.008 · Cited by 52
Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA
Kumar, P., Capodagli, G. C., Awasthi, D., Shrestha, R., Maharaja, K., Sukheja, P., Li, S.-G., Inoyama, D., Zimmerman, M. D., Liang, H.-P. H., et al. (2018) · mBio · doi:10.1128/mbio.02101-17 · Cited by 54
“The FAS-II complex includes one operon that encodes the -ketoacyl-ACP synthases KasA and KasB and the acyl-carrier protein (AcpM) and a second operon that encodes the ketoreductase (MabA) and the enoyl reductase (InhA) (13, 14).”
BackgroundPrice, A. C., Rock, C. O., & White, S. W. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.14.4136-4143.2003 · Cited by 51
“Indeed, triclosan (17, 28) and isoniazid (2) are two commonly used antibacterial agents that are known to target fatty acid synthesis.”
BackgroundHu, Y., Hoffner, S. E., Jiang, W., Wang, W., & Xu, B. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-43 · Cited by 50
Challenges in the development of drugs for the treatment of tuberculosis
Shehzad, A., Rehman, G., Ul‐Islam, M., Khattak, W. A., & Lee, Y. S. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.10.009 · Cited by 55
Xu, X., Vilchèze, C., Av-Gay, Y., Gómez-Velasco, A., & Jacobs, W. R. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00020-11 · Cited by 52
“confer cross-resistance to ETH, a structural analog of INH (1).”
BackgroundSelf-citationJoshi, S. D., Kumar, D., Dixit, S. R., Tigadi, N., More, U. A., Lherbet, C., Aminabhavi, T. M., & Yang, K. S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.025 · Cited by 52
de Vos, M., Derendinger, B., Dolby, T., Simpson, J. A., van Helden, P. D., Rice, J. E., Wangh, L. J., Theron, G., & Warren, R. M. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00531-18 · Cited by 50
Identification and characterization of mycobacteriophage L5 excisionase
Lewis, J. A., & Hatfull, G. F. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01695.x · Cited by 50
“These vectors are also useful for avoiding phenotypes associated with dosage effects of extrachromosomal plasmids (Banerjee et al., 1994; Barsom and Hatfull, 1996).”
BackgroundParrish, N. M., Houston, T. A., Jones, P. B., Townsend, C. A., & Dick, J. D. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1143-1150.2001 · Cited by 50
Baldock, C., Rafferty, J. B., Stuitje, A. R., Slabas, A. R., & Rice, D. W. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2271 · Cited by 50
Molecular Basis of Drug Resistance in Mycobacterium tuberculosis
Cohen, K. A., Bishai, W. R., & Pym, A. S. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0036-2013 · Cited by 61
“Prothionamide is also in the thionamide drug class, and it contains the same active moiety as ETH.”
BackgroundInfluentialFullam, E., Pojer, F., Bergfors, T., Jones, T. A., & Cole, S. T. (2012) · Open Biology · doi:10.1098/rsob.110026 · Cited by 63
Choudhuri, B. S., Sen, S., & Chakrabarti, P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0357 · Cited by 49
Mukherjee, D., Zou, H., Liu, S., Beuerman, R. W., & Dick, T. (2016) · Future Microbiology · doi:10.2217/fmb-2015-0015 · Cited by 50
Fármacos con actividad frente a Mycobacterium tuberculosis
Coll, P. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2009.06.010 · Cited by 67
“La CIM de ETH para M. tuberculosis oscila entre 0,6 y 2,5 (cid:2) g/ml, alcanzándose valores séricos de 20 (cid:2) g/ml a las 3-4 h de una dosis oral de 0,5 a 1 g 49 .”
InfluentialNagy, J. M., Cass, A. E. G., & Brown, K. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31265 · Cited by 49
Comparative Analysis of Legionella pneumophila and Legionella micdadei Virulence Traits
Joshi, A., & Swanson, M. S. (1999) · Infection and Immunity · doi:10.1128/iai.67.8.4134-4142.1999 · Cited by 57
“In an attempt to identify the genetic basis for this difference, we designed a gain-of-function, interspecies complementation strategy applied previously for a variety of pathogenesis model systems (4, 20, 23, 42, 54, 59, 75, 85).”
An effective nano drug delivery and combination therapy for the treatment of Tuberculosis
Sheikhpour, M., Delorme, V., Kasaeian, A., Amiri, V., Masoumi, M., Sadeghinia, M. J., Ebrahimzadeh, N., Maleki, M., & Dizaji, S. P. (2022) · Scientific Reports · doi:10.1038/s41598-022-13682-4 · Cited by 50
Thomas, K. D., Adhikari, A. V., Chowdhury, I. H., Sandeep, T., Mahmood, R., Bhattacharya, B., & Eswaran, S. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.049 · Cited by 48
Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis
Lee, J., Ammerman, N. C., Nolan, S. T., Geiman, D. E., Lun, S., Guo, H., & Bishai, W. R. (2012) · Nature Communications · doi:10.1038/ncomms1724 · Cited by 55
Li, Q., Zhou, M., Fan, X., Yan, J., Li, W., & Xie, J. (2016) · Scientific Reports · doi:10.1038/srep28701 · Cited by 52
Mahapatra, S., Woolhiser, L. K., Lenaerts, A. J. M., Johnson, J. L., Eisenach, K. D., Joloba, M. L., Boom, W. H., & Belisle, J. T. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05486-11 · Cited by 47
“The INH-NAD adducts bind to and inhibit enoyl-acyl carrier protein (ACP) reductase (InhA) (2).”
BackgroundSouza, M. V. N. D., Bispo, M. D. L. F., Pinheiro, A. C., Saraiva, M. F., de Almeida, M. V., & Valle, M. S. (2008) · The Scientific World JOURNAL · doi:10.1100/tsw.2008.99 · Cited by 59
“Compound 15 is reduced by 2-transenoyl-ACP reductase (encoded by InhA gene) to yield the final product 16, which is two carbons longer than the starting substrate 11 and 12, which can be further recycled to produce others derivatives with chains increased by two carbon atoms[14,15].”
BackgroundAlderwick, L. J., Lloyd, G. S., Lloyd, A. J., Lovering, A. L., Eggeling, L., & Besra, G. S. (2010) · Glycobiology · doi:10.1093/glycob/cwq173 · Cited by 52
“Biochemical characterization of the Mycobacterium tuberculosis phosphoribosyl-1-pyrophosphate synthetase”
MethodDrug development against tuberculosis: Past, present and future
Vasava, M. S., Bhoi, M. N., Rathwa, S. K., Borad, M. A., Nair, S., & Patel, H. D. (2017) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2017.03.002 · Cited by 52
Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide
Zhang, H., Xu, Z., Jiang, H., Wu, F., He, X., Liu, Y., Guo, S., Li, Y., Bi, L., Deng, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06289-7 · Cited by 47
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
Motta, I., Calcagno, A., & Bonora, S. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1416093 · Cited by 51
“Usually low-level INH-resistant organisms (often strains bear mutations in the promoter region of the inhA gene [70]) are resistant to ethionamide (ETO), and high-level resistant organisms (usually harboring KatG mutations) are susceptible to ETO.”
BackgroundLiu, L., Jiang, F., Chen, L., Zhao, B. T., Dong, J., Sun, L., Zhu, Y., Liu, B., Zhou, Y., Yang, J., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0184-0 · Cited by 52
Drug-Resistant Tuberculosis in Pediatrics
Swanson, D. S., & Starke, J. R. (1995) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(16)38979-9 · Cited by 51
Ali, A., Hasan, R., Jabeen, K., Jabeen, N., Qadeer, E., & Hasan, Z. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05101-11 · Cited by 47
“with mutations in codon 315 of katG (9, 56).”
BackgroundTimmins, G. S., Master, S. S., Rusnak, F. M., & Deretic, V. P. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.16.5427-5431.2004 · Cited by 51
“Several INH-derived intermediates generated from isoniazid activation, such as isonicotinic acyl NADH (27), and mycobacterial targets including enzymes from the mycobacterial type II fatty acid synthase system (1, 22) have been identified.”
BackgroundBhatt, A., Brown, A. K., Singh, A., Minnikin, D. E., & Besra, G. S. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.07.007 · Cited by 48
“Mycolic acid biosynthesis is essential for mycobacterial survival and many antituberculosis drugs, such as isoniazid, ethionamide, and thiolactomycin, target enzymes of this exclusive pathway (Banerjee et al., 1994; Kremer et al., 2000).”
BackgroundDrug Resistance Evolution of a Mycobacterium tuberculosis Strain from a Noncompliant Patient
Meacci, F., Orrù, G., Iona, E., Giannoni, F., Piersimoni, C., Pozzi, G., Fattorini, L., & Oggioni, M. R. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.7.3114-3120.2005 · Cited by 65
“, kasA (2, 19) or ndh (39), should be postulated.”
BackgroundRecent developments in natural product-based drug discovery for tuberculosis
Dong, M., Pfeiffer, B., & Altmann, K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.015 · Cited by 46
Mariam, S. H., Werngren, J., Aronsson, J., Hoffner, S. E., & Andersson, D. I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021147 · Cited by 48
“tuberculosis infections are isoniazid and rifampicin and resistance to these drugs may be caused by mutations in a number of genes, including inhA, katG, and ndh, (isoniazid) and rpoB (rifampicin) [8–11].”
BackgroundDRUG RESISTANCE IN TUBERCULOSIS
Parsons, L. M., Driscoll, J. R., Taber, H. W., & Salfinger, M. (1997) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70397-4 · Cited by 51
Slow Onset Inhibition of Bacterial β-Ketoacyl-acyl Carrier Protein Synthases by Thiolactomycin
Machutta, C. A., Bommineni, G. R., Luckner, S. R., Kapilashrami, K., Ruzsicska, B. P., Simmerling, C. L., Kisker, C., & Tonge, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.077909 · Cited by 45
Pawełczyk, J., Brzostek, A. M., Kremer, L., Dziadek, B. R., Rumijowska-Galewicz, A., Fiołka, M. J., & Dziadek, J. (2011) · Journal of Bacteriology · doi:10.1128/jb.05638-11 · Cited by 55
“Mycolic acid biosynthesis is also the target of powerful antitubercular drugs, such as isoniazid (INH), ethionamide, and thiolactomycin (3, 27, 31, 44, 53, 70, 72), and an emerging target for future inhibitors.”
BackgroundNiehaus, A. J., Mlisana, K. P., Gandhi, N. R., Mathema, B., & Brust, J. C. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135003 · Cited by 45
“Since the original discovery of inhA, however, many groups have found an association between low-level INH resistance and cross-resistance to ethionamide [5].”
BackgroundAspirin Antagonism in Isoniazid Treatment of Tuberculosis in Mice
Byrne, S. T., Denkin, S. M., & Zhang, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01145-06 · Cited by 46
Torres, M. J., Criado, A. J., Ruíz, M., Llanos, A. C., Palomares, J. C., & Aznar, J. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00521-7 · Cited by 49
“, 1993), and 12-75% of isoniazid-resistant strains have been found to contain mutations either in codon 315 of the katG gene or the inhA ribosomal binding site (Banerjee et al., 1994; Telenti et al., 1997; Zhang et al., 1992).”
BackgroundFang, Z., Doig, C., Rayner, A. W., Kenna, D., Watt, B., & Forbes, K. J. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.998-1003.1999 · Cited by 45
“Three genes have been implicated in INH resistance: katG, encoding catalase-peroxidase, which transforms INH into its active form (41); inhA, encoding a putative mycolic acid synthesis enzyme involved in cell wall synthesis (2); and ahpC, encoding alkyl hydroperoxidase, which functions as a component of antioxidant re…”
BackgroundMunir, A., Kumar, N., Ramalingam, S. B., Tamilzhalagan, S., Shanmugam, S. K., Palaniappan, A. N., Nair, D., Priyadarshini, P., Natarajan, M., Tripathy, S. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46756-x · Cited by 47
Biosynthesis of fatty acids and related metabolites
Rawlings, B. J. (1998) · Natural Product Reports · doi:10.1039/a815275y · Cited by 47
Victor, T. C., Warren, R. M., BUTT, J. L., Jordaan, A. M., FELIX, J. V., Venter, A., Sirgel, F. A., Schaaf, H. S., Donald, P. R., Richardson, M., et al. (1997) · Journal of Medical Microbiology · doi:10.1099/00222615-46-10-847 · Cited by 44
Luo, T., Jiang, L., Sun, W., Fu, G., Mei, J., & Gao, Q. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02046-10 · Cited by 44
“tuberculosis acquires drug resistance mainly through mutations in specific genes (2, 28, 29, 33).”
BackgroundSubstrate Recognition by β-Ketoacyl-ACP Synthases
Borgaro, J. G., Chang, A. T., Machutta, C. A., Zhang, X., & Tonge, P. J. (2011) · Biochemistry · doi:10.1021/bi201199x · Cited by 43
Bardou, F., Quémard, A., Dupont, M. A., Horn, C., Marchal, G., & Daffé, M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.11.2459 · Cited by 43
“Furthermore, application of genetic tools has recently provided new insights into the mechanisms of action of INH (4, 7, 22, 32) and has demonstrated that one target of INH is an enzyme involved in the mycolic acid biosynthesis pathway (4, 22).”
BackgroundMethodInvestigating the Function of the Putative Mycolic Acid Methyltransferase UmaA
Laval, F., Haites, R. E., Movahedzadeh, F., Lemassu, A., Wong, C. Y., Stoker, N. G., Billman‐Jacobe, H., & Daffé, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708859200 · Cited by 50
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.